Education
About Us
Working with TipRanks
Follow Us
Summit Therapeutics (SMMT)
NASDAQ:SMMT
SMMT Analyst Ratings
Moderate Buy
10 Buy
2 Hold
3 Sell
TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers in the past 3 months
SMMT Stock 12 Month Forecast
Average Price Target
$30.82
▲(72.95% Upside)
| Highest Price Target$40.00 | Average Price Target$30.82 | Lowest Price Target$13.00 |
The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.
Detailed List of Analyst Forecasts
Detailed List of Analyst Forecasts
TD Cowen
―
Buy
―
Reiterated
11/10/25
Positive Outlook for Summit Therapeutics Amid Strategic Clinical AdvancementsWe updated our model following Summit's Q3 earnings report during ESMO, and we discussed the earnings details in our management dinner note here and HARMONi-6 ESMO note here. We altered our expense estimates in-line with the ongoing Phase III trials and anticipated initiation of the Phase III HARMONi-GI3 trial. We maintain our Buy rating.
Clear Street
$32
Buy
79.57%
Upside
Reiterated
11/10/25
UBS
$30→$33
Buy
85.19%
Upside
Reiterated
11/10/25
Truist Financial
―
Buy
―
Reiterated
11/10/25
Leerink Partners
―
Sell
―
Reiterated
10/22/25
Barclays
$13→$16
Sell
-10.21%
Downside
Reiterated
10/21/25
Wells Fargo
$30
Buy
68.35%
Upside
Reiterated
10/21/25
H.C. Wainwright
$50→$40
Buy
124.47%
Upside
Reiterated
10/21/25
Evercore ISI
$34
Buy
90.80%
Upside
Reiterated
10/20/25
Piper Sandler
$21
Hold
17.85%
Upside
Reiterated
10/20/25
Citi
$35→$40
Buy
124.47%
Upside
Reiterated
10/20/25
Citizens JMP
$40
Buy
124.47%
Upside
Reiterated
09/08/25
Guggenheim
$40
Buy
124.47%
Upside
Initiated
09/03/25
Analyst Type
Any
Ranks
Any
Analyst Rating
Any
Upside/ Downside
Any
Action
Any
TD Cowen
―
Buy
―
Reiterated
11/10/25
Positive Outlook for Summit Therapeutics Amid Strategic Clinical AdvancementsWe updated our model following Summit's Q3 earnings report during ESMO, and we discussed the earnings details in our management dinner note here and HARMONi-6 ESMO note here. We altered our expense estimates in-line with the ongoing Phase III trials and anticipated initiation of the Phase III HARMONi-GI3 trial. We maintain our Buy rating.
Clear Street
$32
Buy
79.57%
Upside
Reiterated
11/10/25
UBS
$30→$33
Buy
85.19%
Upside
Reiterated
11/10/25
Truist Financial
―
Buy
―
Reiterated
11/10/25
Leerink Partners
―
Sell
―
Reiterated
10/22/25
Barclays
$13→$16
Sell
-10.21%
Downside
Reiterated
10/21/25
Wells Fargo
$30
Buy
68.35%
Upside
Reiterated
10/21/25
H.C. Wainwright
$50→$40
Buy
124.47%
Upside
Reiterated
10/21/25
Evercore ISI
$34
Buy
90.80%
Upside
Reiterated
10/20/25
Piper Sandler
$21
Hold
17.85%
Upside
Reiterated
10/20/25
Citi
$35→$40
Buy
124.47%
Upside
Reiterated
10/20/25
Citizens JMP
$40
Buy
124.47%
Upside
Reiterated
09/08/25
Guggenheim
$40
Buy
124.47%
Upside
Initiated
09/03/25
Best Analysts Covering Summit Therapeutics
1 Month
xxx
Success Rate
6/10 ratings generated profit
Average Return
+5.88%
reiterated a xxx
rating last month
Copying xxxxxxxxxxxxxxxxxx
trades and holding each position for 1 Month would result in 60.00% of your transactions generating a profit, with an average return of +5.88% per trade.
3 Months
xxx
Success Rate
6/6 ratings generated profit
Average Return
+22.63%
reiterated a xxx
rating 6 months ago
Copying xxxxxxxxxxxxxxxxxx
trades and holding each position for 3 Months would result in 100.00% of your transactions generating a profit, with an average return of +22.63% per trade.
1 Year
Success Rate
5/7 ratings generated profit
Average Return
+229.90%
initiated a buy rating 3 months ago
Copying Bradley Canino's trades and holding each position for 1 Year would result in 71.43% of your transactions generating a profit, with an average return of +229.90% per trade.
2 Years
xxx
Success Rate
4/7 ratings generated profit
Average Return
+140.17%
initiated a xxx
rating 3 months ago
Copying xxxxxxxxxxxxxxxxxx
trades and holding each position for 2 Years would result in 57.14% of your transactions generating a profit, with an average return of +140.17% per trade.
The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.
SMMT Analyst Recommendation Trends
Rating
Jul 25
Aug 25
Sep 25
Oct 25
Nov 25
Strong Buy
11
11
13
18
17
Buy
14
17
14
16
10
Hold
1
1
1
2
2
Sell
3
3
5
5
5
Strong Sell
0
1
2
3
2
total
29
33
35
44
36
Each month's total comprises the sum of three months' worth of ratings.
SMMT Financial Forecast
SMMT Stock Forecast FAQ
What is SMMT’s average 12-month price target, according to analysts?
Based on analyst ratings, Summit Therapeutics’s 12-month average price target is 30.82.
What is SMMT’s upside potential, based on the analysts’ average price target?
Summit Therapeutics has 72.95% upside potential, based on the analysts’ average price target.
Can I see which stocks the top-ranking analysts are rating?
Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.
How can I follow the stock ratings of top Wall Street analysts?
Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.
Is SMMT a Buy, Sell or Hold?
Summit Therapeutics has a consensus rating of Moderate Buy which is based on 10 buy ratings, 2 hold ratings and 3 sell ratings.
What is Summit Therapeutics’s price target?
The average price target for Summit Therapeutics is 30.82. This is based on 15 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
The highest analyst price target is $40.00 ,the lowest forecast is $13.00. The average price target represents 72.95% Increase from the current price of $17.82.
The highest analyst price target is $40.00 ,the lowest forecast is $13.00. The average price target represents 72.95% Increase from the current price of $17.82.
What do analysts say about Summit Therapeutics?
Summit Therapeutics’s analyst rating consensus is a Moderate Buy. This is based on the ratings of 15 Wall Streets Analysts.
How can I buy shares of SMMT?
Open a brokerage account, see exclusive account opening deals on our Best Online Brokers page.